{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "VOR",
  "name": "Vor Biopharma Inc.",
  "url": "https://frontierpicks.com/dossiers/VOR/",
  "json_url": "https://frontierpicks.com/dossiers/VOR.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Legacy-pivot re-rating held its breakout through the 2026-08-11 Q2 miss — $23.36 close on 2026-08-21 against $23.67 on 08-07 — but the same release disclosed $48.4M of ATM stock sold into July strength. With UPSTREAM MG topline guided 1H2027 and the Q2 print behind it, no dated company event now sits inside 30 days.",
  "invalidation_trigger": "A weekly close below $20 loses the post-print consolidation and returns price into the $19–$21 shelf that capped the tape through early July; secondary condition: ATM issuance above the July $48.4M pace disclosed in the Q3 10-Q, or any slip in the 1H2027 UPSTREAM MG topline guide.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "semi-foundry-equipment"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Ex-Greater China rights only: RemeGen retains Greater China and receives milestones plus tiered royalties on telitacicept.",
    "Single-asset structure — telitacicept carries the entire equity story after trem-cel/VCAR33 were wound down in 2025.",
    "All approvals to date are Chinese (NMPA): SLE, RA, gMG, IgA nephropathy (conditional), Sjogren's. No US, EU or Japan approval exists.",
    "The June 2025 RemeGen license included $80M of penny warrants at a $0.0001 strike, separate from the $45M cash upfront."
  ],
  "body_markdown": "## Current Thesis\nThe narrative leg is unchanged in shape and now carries one resolved question and one new one. Vor wound down trem-cel/VCAR33 and in June 2025 in-licensed telitacicept, a dual BLyS/APRIL TACI-Fc already approved in China, from RemeGen; the equity is re-rating off that pivot. Since the last note the Q2 print landed on 2026-08-11 and the tape did not break on it — GAAP loss per share of $(1.16) against a $(0.70) consensus, adjusted $(0.80), and the last completed daily close was $23.36 on 2026-08-21 versus $23.67 on 2026-08-07. What the print added was dilution detail: cash of $466.1M at June 30, 2026, plus $48.4M of net proceeds from at-the-market sales *during July 2026*, for a pro-forma $514.5M and a runway guide into early 2029. The company sold stock into the July advance while already guiding funded past the readout.\n\nThe narrative is **maturing**. Headline flow since 2026-06-08 has been housekeeping and sell-side catch-up — board change 2026-07-07, inducement grants 2026-07-02 and 2026-08-03, Wedbush raising its target to $27 from $18 on 2026-08-12 while keeping a Neutral rating. Coverage is re-marking to a tape that already moved, which is late-phase behaviour for a leg, but no mainstream retail-sentiment cluster has formed and the participation base is still specialist. The event that settles the story, global Phase 3 UPSTREAM MG topline, is guided to 1H 2027.\n\n## Bull Case\n- **The binary is fully funded.** Pro-forma $514.5M reported 2026-08-11 ($466.1M at 06-30 plus $48.4M July ATM net proceeds), runway into early 2029 — past the 1H2027 UPSTREAM MG topline and the SjD program behind it.\n- **Burn is now a development burn, not a wind-down burn.** Q2 2026 R&D was $25.9M against $261.5M in Q2 2025; net loss $62.8M against $1,573.7M a year earlier, when the cell-therapy write-offs ran through the P&L.\n- **Both global Phase 3s are enrolling.** UPSTREAM MG and UPSTREAM SjD were both described as \"enrollment ongoing\" in the 2026-08-11 release, with MG topline reaffirmed for 1H 2027.\n- **The China dataset is peer-reviewed.** TELIGAN interim Phase 3 in IgA nephropathy showed a 58.9% reduction in urine protein-to-creatinine ratio at week 39 versus 8.8% for placebo, published in NEJM and reported 2026-05-14.\n- **Five approved China indications.** NMPA added conditional approval in IgA nephropathy and approval in Sjögren's disease on 2026-06-08, on top of SLE, RA and gMG.\n- **The tape absorbed a miss.** The 2026-08-11 EPS shortfall did not return price to the pre-breakout shelf; ten sessions later the close was $23.36.\n\n## Bear Case\n- **Issuance into strength is now a fact, not a risk.** The $48.4M of ATM sales occurred in July 2026, the month price broke out of the high-teens shelf, and were disclosed only with the 2026-08-11 release. The program's remaining capacity is not a matter of guidance.\n- **The near-term calendar is empty.** With Q2 reported, the next company-scheduled event is the Q3 print, and the decision-grade readout is ten months out.\n- **One asset carries the whole equity.** Rights are ex-Greater China only; RemeGen retains Greater China plus milestones and tiered royalties. There is no second program to absorb a global miss.\n- **The 52-week frame is still broken.** Price sits 52.1% below the adjusted 52-week high of $48.72 — this leg is a recovery inside prior damage.\n- **Occupied indication.** FcRn blockade in gMG (argenx Vyvgart, UCB rozanolixizumab, J&J nipocalimab) is entrenched, and Vera Therapeutics' atacicept is the closest dual BAFF/APRIL comparator; telitacicept has to bridge Chinese effect sizes into a Western registrational cohort to matter commercially.\n- **Wedbush stayed Neutral at $27.** The 2026-08-12 revision raised the number and not the rating, and $27 sits modestly above the 2026-08-21 close.\n\n## Setup & Price Structure\n- Last completed daily close $23.36 on 2026-08-21; RSI(14) 64.6, down from 79.3 on 2026-08-07 while price barely moved — the momentum reading cooled sideways rather than through a drawdown.\n- The trailing three-month price change reads +63.0% as of 2026-08-21 against +39.7% as of 2026-08-07. The increase comes from the trailing reference rolling forward past the May trough; it is a window artifact, not fresh upside.\n- Structure to defend: the $19–$21 shelf that capped the tape through early July 2026, and the post-print consolidation above it. Employee inducement grant strikes track the advance step by step — $13.85 on 2026-05-04, $14.57 on 2026-06-01, $18.39 on 2026-07-02, $21.15 on 2026-08-01.\n- Distance from the adjusted 52-week high of $48.72: 52.1%.\n- Crowding/positioning observables, stated as observables: equity issued into the July advance ($48.4M net ATM); one sell-side revision in the window and it kept a Neutral rating; aggregator targets are dispersed — public.com shows an average of $39.00 with a $50 high and a $27 low, while MarketBeat had carried $45.33 across 10 analysts in early August; no earnings date inside the next 30 days now that Q2 has cleared.\n\n## Catalyst Calendar (next 30 days)\n- **No company-confirmed event between 2026-08-22 and 2026-09-21.** The Q2 print (2026-08-11) was the near-term binary and it has come and gone.\n- **~2026-11-10 (est.)** — Q3 2026 results. Q2 was reported 2026-08-11 and Q1 on 2026-05-13, so early-to-mid November is a pattern estimate, not a scheduled date. It is the next disclosure of ATM share sales after July's $48.4M and of any change to the early-2029 runway guide.\n- **~2027-05-31 (est.)** — UPSTREAM MG topline, guided 1H 2027 as of 2026-08-11. Everything between the $23.36 tape and the four-handle aggregator targets resolves there.\n- Unscheduled and possible at any time: a prospectus supplement or marketed offering, and medical-meeting presentations of RemeGen's China datasets, which have moved the name before without being on a corporate calendar.\n\n## What Would Change Our Mind\nThe structure that matters is the shelf the July breakout cleared. Losing the post-print consolidation and settling back into the $19–$21 range — a weekly close below $20 — Second, if the Q3 10-Q shows ATM sales running above the July pace of $48.4M net, the early-2029 runway guide stops being the reason the readout is de-risked and starts being the reason the share count keeps rising. Third, any language change on UPSTREAM MG — enrollment described as other than ongoing, or topline moving out of 1H 2027 — removes the only dated anchor the equity has. On the other side, a US or EU regulatory interaction disclosed on a quarterly call, or a global-cohort interim that reads consistent with the 4.83-point placebo-adjusted MG-ADL result from China, would move this out of the recovery-leg category.\n\n## Correlation Notes\n- **RemeGen (HKEX 9995 / SSE 688331)** is the upstream read-through: it runs the Greater China commercial base, retains milestone and royalty economics, and generates the data that the Western case is built on.\n- **Vera Therapeutics (VERA)** is the mechanism comparator — atacicept, dual BAFF/APRIL — and its readouts reprice the class, not just the company.\n- **argenx (ARGX), UCB, J&J (JNJ)** define the gMG competitive bar; a label expansion or head-to-head result there compresses the commercial slot telitacicept is aiming at.\n- **XBI/biotech beta and the rate path** dominate the daily variance in a pre-revenue single-asset name with no US approval; the 2026-08-11 miss moved less than a typical XBI-beta day would suggest, which is worth watching for whether idiosyncratic flow is actually setting the price here.",
  "first_seen": "2026-07-12",
  "last_analyzed": "2026-08-22T11:21:01+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}